Nanobiotix SA

Voting Rights and Shares Capital of the Company

12 Sep 2025 10:00:00 By Nasdaq GlobeNewswire

Nanobiotix to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

02 Sep 2025 13:15:00 By Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

26 Aug 2025 23:00:00 By Nasdaq GlobeNewswire

NANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3)

07 Jul 2025 13:15:00 By Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

10 Jun 2025 13:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX to Participate in the Jefferies Global Healthcare Investor Conference

27 May 2025 23:00:00 By Nasdaq GlobeNewswire

Nanobiotix Provides First Quarter 2025 Operational and Financial Update

21 May 2025 13:15:00 By Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

13 May 2025 23:00:00 By Nasdaq GlobeNewswire

Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ

11 May 2025 23:00:00 By Nasdaq GlobeNewswire

Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer

04 May 2025 23:00:00 By Nasdaq GlobeNewswire

Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call

29 Apr 2025 23:00:00 By Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

14 Apr 2025 13:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results

02 Apr 2025 13:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025

30 Mar 2025 23:00:00 By Nasdaq GlobeNewswire

Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC

27 Mar 2025 13:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference

20 Mar 2025 13:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026

17 Mar 2025 13:15:00 By Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

13 Mar 2025 14:15:00 By Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

12 Feb 2025 13:15:00 By Nasdaq GlobeNewswire

Nanobiotix to Participate in Multiple Investor Conferences in February and March 2025

29 Jan 2025 13:15:00 By Nasdaq GlobeNewswire